期刊文献+

地特胰岛素联合二甲双胍和(或)阿卡波糖对肥胖的2型糖尿病的治疗观察 被引量:1

下载PDF
导出
摘要 目的观察地特胰岛素联合二甲双胍和(或)阿卡波糖对肥胖的2型糖尿病病人的治疗效果。方法选取50例在我科治疗的口服药物控制不佳的肥胖的2型糖尿病患者,给予地特胰岛素联合二甲双胍和(或)阿卡波糖治疗,在治疗前后进行相应指标的记录、对比、分析。结果治疗后3个月、6个月血糖水平及HbAlc均明显下降,与治疗前相比,差异有显著性(P<0.001),在治疗过程中血糖下降缓和,血糖波动不大,无明显低血糖发生,空腹C肽在治疗3个月时就有升高,治疗6个月时与治疗前、治疗3个月时相比均有升高,有统计学意义(P<0.001)。餐后2hC肽3个月时有升高,具统计学意义(P<0.001),治疗6个月时有继续升高但无统计学意义。结论地特胰岛素联合二甲双胍和(或)阿卡波糖对肥胖的2型糖尿病患者有很好的降糖疗效和安全性,有效降低血糖,持久达标,低血糖风险低,是肥胖的2型糖尿病患者较理想的选择方案。
出处 《海峡药学》 2012年第6期189-191,共3页 Strait Pharmaceutical Journal
  • 相关文献

参考文献5

二级参考文献54

  • 1The Diabetes Control and Complications Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care, 1995,18 : 1415-1427.
  • 2UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998,352: 837 -853.
  • 3Yki-Jarvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1997,82 : 4037-4043.
  • 4DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care, 1988,11 : 567-573.
  • 5Lin X, Taguchi A,Park S, et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and dia betes. J Clin Invest,2004,114:908-916.
  • 6Brunner GA, Sendhofer G, Wutte A, et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes, 2000,108 : 100-105.
  • 7Havelund S, Ribel U, Plum A, et al. The mechanism of protraction of insulin detemir, a long acting, acylated analogue of human insulin. Diabetes, 2004,53 : P462.
  • 8Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insu lins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia, 2004,47 : 622-629.
  • 9Raslovd K, Bogoev M, Raz I,et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract, 2004,66:193-201.
  • 10Haak T, Tiengo A, Draeger E,et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab, 2005,7 : 56-64.

共引文献198

同被引文献4

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部